Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Zhaoke BRIMOCHOL-PF Taiwan License Targets Presbyopia Market

Fineline Cube Dec 9, 2025
Company Deals

Shanghai Pharma X842 Deal Termination with Sinorda

Fineline Cube Dec 8, 2025
Company Deals Medical Device

Mirxes XtalPi AI Platform Targets Asian GI Cancers

Fineline Cube Dec 8, 2025
Company Deals Drug

Sirnaomics ChemPartner GalAhead Nucleic-Acid Deal

Fineline Cube Dec 8, 2025
Company Deals

OTR Therapeutics Series-A Raises $100M for Neurology Pipeline

Fineline Cube Dec 8, 2025
Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025
Company Drug

Kexing GB10 nAMD Injection Secures NMPA Clinical Trial Approval

Fineline Cube Dec 9, 2025
Company Drug

Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy

Fineline Cube Dec 9, 2025
Policy / Regulatory

CDE Seeks Public Feedback on New Drug Benefit-Risk Assessment Guidelines

Fineline Cube Nov 9, 2022

The Center for Drug Evaluation (CDE) has released the “New Drug Benefit-Risk Assessment Technical Guidelines,”...

Company Deals

Zhaoke Ophthalmology Licenses C&V Tech’s TONO-i Tonometer for Greater China

Fineline Cube Nov 9, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) spin-off Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...

Policy / Regulatory

CDE Releases Draft Guidelines on New Drug Benefit-Risk Assessment

Fineline Cube Nov 9, 2022

The Center for Drug Evaluation (CDE) has released the “New Drug Benefit-Risk Assessment Technical Guidelines,”...

Company Deals

Insilico Medicine Partners with Sanofi for AI-Driven Drug Discovery

Fineline Cube Nov 9, 2022

Insilico Medicine, an artificial intelligence (AI)-driven drug discovery company based in Hong Kong, has announced...

Policy / Regulatory

CDE Releases Guidelines on Pediatric Anti-tumor Drug Development

Fineline Cube Nov 9, 2022

The Center for Drug Evaluation (CDE) has released a Technical Guidelines document focused on “Clinical...

Company Deals

Pfizer Partners with CARD, CSAF, and PingAn Good Doctor at CIIE

Fineline Cube Nov 9, 2022

The 5th China International Import Expo (CIIE) saw the announcement of a partnership between US-based...

Company Deals

Pfizer China Partners with Alibaba Health for Disease Education at CIIE

Fineline Cube Nov 9, 2022

The 5th China International Import Expo (CIIE) saw US-based Pfizer’s China unit announce a partnership...

Company Deals

Adicon Partners with Illumina to Advance Oncology Detection Assay TSO 500

Fineline Cube Nov 9, 2022

China-based Adicon Holdings Limited has announced a strategic partnership with US-based Illumina (NASDAQ: ILMN) at...

Company Deals

Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure

Fineline Cube Nov 9, 2022

US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA),...

Company Deals

Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure

Fineline Cube Nov 9, 2022

US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA),...

Company Drug

MicuRx Pharmaceuticals Doses First Patient in China for MRX-8 Trial

Fineline Cube Nov 9, 2022

Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals (SHA: 688373) has announced the first patient dosing in...

Company Drug

Zhifei Bio Initiates Global Study for Omicron-Delta COVID-19 Vaccine in Uzbekistan

Fineline Cube Nov 9, 2022

China-based Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd has announced the initiation of a global clinical study...

Company Deals

Mainline Biosciences Raises RMB 100M in Series A Financing for Peptide Drugs

Fineline Cube Nov 9, 2022

Mainline Biosciences, a polypeptide drug developer based in Zhongshan, has reportedly raised close to RMB...

Company Deals

Jiangsu Trausim Raises RMB 100M in Series A Financing for Dental Implants

Fineline Cube Nov 9, 2022

China-based Jiangsu Trausim Medical Instrument Co., Ltd, a wholly-owned subsidiary of Fulong Holdings and focused...

Company Drug

Cyramza Prescribed in China for Advanced Gastric Cancer

Fineline Cube Nov 9, 2022

Cyramza (ramucirumab) was first prescribed on November 6, 2022, at the Zhongshan Hospital in Shanghai...

Company Deals

Merck KGaA Collaborates with Biotheus to Accelerate Cell Line Characterization

Fineline Cube Nov 9, 2022

German pharmaceutical giant Merck KGaA (ETR: MRK) has announced a collaboration with Biotheus, a China-based...

Company Drug

Merck’s Keytruda Receives 10th Indication Approval in China for TNBC

Fineline Cube Nov 9, 2022

US-based Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab) has...

Company Deals

Takeda Partners with CCCMHPIE to Boost Rare Disease Drug Access in China

Fineline Cube Nov 8, 2022

The 5th China International Import Expo (CIIE) saw Japan-based Takeda Pharmaceutical Co., Ltd’s China unit...

Company Deals

Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies

Fineline Cube Nov 8, 2022

Xellsmart, a stem-cell startup based in Suzhou, has reportedly raised over RMB 200 million (USD...

Company

Novo Nordisk Reports 16% YOY Growth in Q3, Raises Full-Year Guidance

Fineline Cube Nov 8, 2022

Denmark-based biopharma Novo Nordisk A/S (NYSE: NVO) has released its Q3 2022 earnings report. The...

Posts pagination

1 … 533 534 535 … 595

Recent updates

  • Zhaoke BRIMOCHOL-PF Taiwan License Targets Presbyopia Market
  • Kexing GB10 nAMD Injection Secures NMPA Clinical Trial Approval
  • Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy
  • Ignis Therapeutics Solriamfetol NMPA Approval Targets OSA Sleepiness
  • Abbisko ABSK043 NSCLC Combo Shows 71% Disease Control at ESMO Asia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Zhaoke BRIMOCHOL-PF Taiwan License Targets Presbyopia Market

Company Drug

Kexing GB10 nAMD Injection Secures NMPA Clinical Trial Approval

Company Drug

Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy

Company Drug

Ignis Therapeutics Solriamfetol NMPA Approval Targets OSA Sleepiness

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.